Nippon Shinyaku Co. Ltd. Announces Consolidated Earnings Results for the Third Quarter Ended December 31, 2019; Provides Earnings Guidance for the Full Year Ending March 31, 2020
February 04, 2020
Share
Nippon Shinyaku Co. Ltd. announced consolidated earnings results for the third quarter ended December 31, 2019. For the quarter, the company reported net sales of JPY 88,113 million compared with JPY 87,019 million for the same period a year ago. Operating income was JPY 15,466 million compared with JPY 16,435 million for the same period a year ago. Profit was JPY 11,902 million or JPY 176.47 per basic share compared with JPY 12,713 million or JPY 188.52 per basic share for the same period a year ago.
For the full year ending March 31, 2020, the company expects to report net sales of JPY 116,000 million, operating income of JPY 21,000 million, and net income attributable to owners of the parent of JPY 16,500 million or JPY 244.97 per share.
Nippon Shinyaku Co., Ltd. is a Japan-based company principally involved in the manufacture and sale of pharmaceutical products and functional foodstuffs. The Company operates in two business segments. The Pharmaceutical segment is involved in the manufacture and sale of urinary system therapeutic agents, blood cancer therapeutic agents, pain, inflammation and allergic therapeutic agents, digestive system therapeutic agents, cardiovascular systems and metabolic therapeutic agents. The Functional Foodstuff segment involves in the manufacture and sale of health food materials, quality stability preservatives, protein preparation, spice and seasoning products. The Company is also involved in the business support business, non-life insurance agency business, as well as the provision of real estate leasing services.
Nippon Shinyaku Co. Ltd. Announces Consolidated Earnings Results for the Third Quarter Ended December 31, 2019; Provides Earnings Guidance for the Full Year Ending March 31, 2020
NIPPON SHINYAKU CO., LTD. 
